{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:28:37Z","timestamp":1793726917838,"version":"4.6.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,22]],"date-time":"2021-02-22T00:00:00Z","timestamp":1613952000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006396","name":"Alexion Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006396","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.msard.2021.102849","type":"journal-article","created":{"date-parts":[[2021,2,21]],"date-time":"2021-02-21T11:45:58Z","timestamp":1613907958000},"page":"102849","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8672-8419","authenticated-orcid":false,"given":"Ho Jin","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanthi","family":"Viswanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai-Chen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulian","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus","family":"Yountz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1608-8206","authenticated-orcid":false,"given":"Dean M.","family":"Wingerchuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean J.","family":"Pittock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9650-6222","authenticated-orcid":false,"given":"Achim","family":"Berthele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Totolyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Palace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Fujihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 1","key":"10.1016\/j.msard.2021.102849_bib0001","first-page":"103","article-title":"Pharmacokinetic\/pharmacodynamic properties of eculizumab support established efficacy in patients with NMOSD: findings from the phase 3 PREVENT study","volume":"27","author":"Berthele","year":"2020","journal-title":"Eur. J. Neurol."},{"issue":"48","key":"10.1016\/j.msard.2021.102849_bib0002","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1016\/j.vaccine.2016.10.022","article-title":"Meningococcal disease in the Asia-Pacific region: findings and recommendations from the Global Meningococcal Initiative","volume":"34","author":"Borrow","year":"2016","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.msard.2021.102849_bib0003","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood-2007-06-094136","article-title":"Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria","volume":"111","author":"Brodsky","year":"2008","journal-title":"Blood"},{"issue":"10206","key":"10.1016\/j.msard.2021.102849_bib0004","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.msard.2021.102849_bib0005","unstructured":"EuroQol Research Foundation, 2018. EQ-5D-3L user guides. 2018. https:\/\/euroqol.org\/publications\/user-guides. Accessed December 7, 2020."},{"issue":"5","key":"10.1016\/j.msard.2021.102849_bib0006","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/ana.24617","article-title":"Epidemiology of aquaporin-4 autoimmunity and neuromyelitis optica spectrum","volume":"79","author":"Flanagan","year":"2016","journal-title":"Ann. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2021.102849_bib0007","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s40265-020-01297-w","article-title":"Eculizumab: a review in neuromyelitis optica spectrum disorder","volume":"80","author":"Frampton","year":"2020","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.msard.2021.102849_bib0008","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1056\/NEJM198301273080401","article-title":"Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH","volume":"308","author":"Hauser","year":"1983","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.msard.2021.102849_bib0009","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa061648","article-title":"The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria","volume":"355","author":"Hillmen","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.102849_bib0010","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front. Neurol."},{"issue":"12","key":"10.1016\/j.msard.2021.102849_bib0011","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"issue":"1","key":"10.1016\/j.msard.2021.102849_bib0012","first-page":"45","article-title":"ICH harmonized tripartite guideline: guideline for good clinical practice","volume":"47","year":"2001","journal-title":"J. Postgrad. Med."},{"issue":"14","key":"10.1016\/j.msard.2021.102849_bib0013","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1212\/WNL.0b013e3182a6cb5c","article-title":"Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica","volume":"81","author":"Jiao","year":"2013","journal-title":"Neurology"},{"issue":"22","key":"10.1016\/j.msard.2021.102849_bib0014","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000006574","article-title":"Racial differences in neuromyelitis optica spectrum disorder","volume":"91","author":"Kim","year":"2018","journal-title":"Neurology"},{"issue":"Pt 6","key":"10.1016\/j.msard.2021.102849_bib0015","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1093\/brain\/aws109","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan","volume":"135","author":"Kitley","year":"2012","journal-title":"Brain"},{"issue":"11","key":"10.1016\/j.msard.2021.102849_bib0016","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.msard.2021.102849_bib0017","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/biom.12528","article-title":"On confidence intervals for the hazard ratio in randomized clinical trials","volume":"72","author":"Lin","year":"2016","journal-title":"Biometrics"},{"issue":"2","key":"10.1016\/j.msard.2021.102849_bib0018","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/j.1399-0039.2008.01172.x","article-title":"Association of the HLA-DPB1*0501 allele with anti-aquaporin-4 antibody positivity in Japanese patients with idiopathic central nervous system demyelinating disorders","volume":"73","author":"Matsushita","year":"2009","journal-title":"Tissue Antigens"},{"issue":"9","key":"10.1016\/j.msard.2021.102849_bib0019","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1001\/archneurol.2012.314","article-title":"Epidemiology of neuromyelitis optica in the United States: a multicenter analysis","volume":"69","author":"Mealy","year":"2012","journal-title":"Arch. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2021.102849_bib0020","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1056\/NEJMoa1311084","article-title":"Genetic variants in C5 and poor response to eculizumab","volume":"370","author":"Nishimura","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.msard.2021.102849_bib0021","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1093\/brain\/awz054","article-title":"Outcome prediction models in AQP4-IgG positive neuromyelitis optica spectrum disorders","volume":"142","author":"Palace","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.msard.2021.102849_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102641","article-title":"Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: subgroup analyses of the randomized controlled phase 3 PREVENT trial","volume":"47","author":"Palace","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.msard.2021.102849_bib0023","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1177\/1352458515572406","article-title":"Demographic and clinical features of neuromyelitis optica: a review","volume":"21","author":"Pandit","year":"2015","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.102849_bib0024","doi-asserted-by":"crossref","first-page":"A1","DOI":"10.1016\/j.msard.2019.07.001","article-title":"Editorial on: eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"33","author":"Pardo","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.msard.2021.102849_bib0025","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2021.102849_bib0026","first-page":"1","article-title":"Response to: eculizumab package insert recommendations for meningococcal vaccinations: call for clarity and a targeted approach for use of the drug in neuromyelitis optica spectrum disorder","author":"Pittock","year":"2020","journal-title":"CNS Spectr."},{"issue":"3","key":"10.1016\/j.msard.2021.102849_bib0027","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.1212\/NXI.0000000000000225","article-title":"Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus","volume":"3","author":"Sepulveda","year":"2016","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2021.102849_bib0028","unstructured":"Soliris Australia Product Information, 2019. SOLIRIS\u00ae (eculizumab) [Australia Product Information], July 2020. Alexion Pharmaceuticals, Inc., USA. https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent&id=CP-2010-PI-02947-3&d=202007241016933. Accessed 23 November 2020."},{"key":"10.1016\/j.msard.2021.102849_bib0029","unstructured":"Soliris US Prescribing Information, 2019. SOLIRIS\u00ae (eculizumab) [US Prescribing Information], June 2019. Alexion Pharmaceuticals, Inc., USA. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125166s431lbl.pdf. Accessed November 11, 2020."},{"issue":"17\u201318","key":"10.1016\/j.msard.2021.102849_bib0030","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S0161-5890(96)00078-8","article-title":"Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv","volume":"33","author":"Thomas","year":"1996","journal-title":"Mol. Immunol."},{"issue":"5","key":"10.1016\/j.msard.2021.102849_bib0031","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.msard.2021.102849_bib0032","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/01.STR.19.5.604","article-title":"Interobserver agreement for the assessment of handicap in stroke patients","volume":"19","author":"van Swieten","year":"1988","journal-title":"Stroke"},{"issue":"11","key":"10.1016\/j.msard.2021.102849_bib0034","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1177\/1352458518792430","article-title":"A nationwide epidemiological study on the prevalence of multiple sclerosis and neuromyelitis optica spectrum disorder with important multi-ethnic differences in Malaysia","volume":"25","author":"Viswanathan","year":"2019","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2021.102849_bib0033","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.msard.2018.07.003","article-title":"Multiple sclerosis and neuromyelitis optica spectrum disorders in Malaysia: a comparison in different ethnic groups","volume":"25","author":"Viswanathan","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"7","key":"10.1016\/j.msard.2021.102849_bib0035","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1017\/S0950268811000574","article-title":"Meningococcal disease in Asia: an under-recognized public health burden","volume":"139","author":"Vyse","year":"2011","journal-title":"Epidemiol. Infect."},{"issue":"1\u20132","key":"10.1016\/j.msard.2021.102849_bib0036","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jneuroim.2010.11.004","article-title":"HLA-DPB1 0501 is associated with susceptibility to anti-aquaporin-4 antibodies positive neuromyelitis optica in southern Han Chinese","volume":"233","author":"Wang","year":"2011","journal-title":"J. Neuroimmunol."},{"issue":"9","key":"10.1016\/j.msard.2021.102849_bib0037","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1136\/jnnp-2015-312601","article-title":"Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica","volume":"87","author":"Waters","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"10","key":"10.1016\/j.msard.2021.102849_bib0039","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.msard.2021.102849_bib0038","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2021.102849_bib0040","unstructured":"World Medical Association, 2013. WMA Declaration of Helsinki \u2014 ethical principles for medical research involving human subjects. Ferney-Voltaire, France: World Medical Association, October 2013 (https:\/\/www.wma.net\/policies-post\/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects\/)."},{"issue":"22","key":"10.1016\/j.msard.2021.102849_bib0041","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N. Engl. J. Med."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821001152?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034821001152?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:52:08Z","timestamp":1761900728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034821001152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":41,"alternative-id":["S2211034821001152"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2021.102849","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Eculizumab in Asian patients with anti-aquaporin-IgG-positive neuromyelitis optica spectrum disorder: A subgroup analysis from the randomized phase 3 PREVENT trial and its open-label extension","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2021.102849","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102849"}}